Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event is HUGE!!
OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event
APRIL 19, 2017 BY Joana Fernandes, PhD IN NEWS
OWC Pharmaceutical Research will give a presentation in Monaco next week on cannabis-based therapies, which studies have shown help people with fibromyalgia, psoriasis and other inflammatory conditions.
Yehuda Baruch, the company’s chief science officer, will talk about “Cannabis And The Endocannabinoid System: A New And Emerging Pipeline For Medical Products,” at the Monaco Growth Forums Spring Edition, April 25-26.
A key aim is to create interest in cannabis-based therapies in Europe, the company acknowledged.
Cannabis-based treatments have been gaining momentum as a valuable option across a growing range of diseases, including fibromyalgia, psoriasis, multiple myeloma, and migraine headaches. OWC is working on appropriate doses and delivery systems for medical cannabis.
Cannabidiol, the plant’s pure molecular compound, has anti-inflammatory and pain-relieving properties, and no known psycho-active effects. Research has shown that cannabidiol can be an effective treatment for many types of pain, particularly inflammatory pain.
Among those who benefit from cannabis pain relief are fibromyalgia patients, studies have shown. One testament to the treatment was an online survey of more than 1,300 fibromyalgia patients in 2016. Many respondents said cannabis did a better job of treating their symptoms than therapies that the U.S. Food and Drug Administration (FDA) has approved.
A clinical trial has shown that a cannabinoid-based therapy also reduced inflammatory markers in psoriasis. The results suggested it could be used against other inflammation-related disorders.
“We are very excited to participate in this prestigious European event, and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ [medical marijuana] clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first,” Mordechai Bignitz, the CEO of OWC, said in a news release. “We anticipate that together with some states in the U.S. and Canada, Europe can soon become a primary market for our products.”
Andreea Porcelli, CEO of Monaco Growth Forums, added: “We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area.”
https://fibromyalgianewstoday.com/2017/04/19/owc-to-discuss-cannabis-based-therapies-for-fibromyalgia-at-monaco-event/
-------------------------------------------
This Monaco Growth Forums event coming up in less than a week is a really big deal. Dr. Yehuda Baruch, OWCP’s CSO & CTO, will also be a Keynote Speaker at MGF’s Cocktail Reception on Wednesday, April 26th. The keynote topic will be “Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.” https://monacogrowthforums.com/2017/04/owc-pharmaceutical-research-corp-to-present-at-monaco-growth-forums-in-monaco/
MMJ is a very hot emerging market that big investors want to be in and OWCP has been chosen to present their position in this space to 475 institutional investors from over 44 countries, including heads of family offices, fund managers, and private asset managers from major institutions. All attendees at MGF events foster a shared interest in high-growth companies. There will for sure be many institutional investors interested in OWCP. With solid financial backing OWCP can take off and blow expectations away. https://monacogrowthforums.com/about/
Check out the exposure OWCP is getting listed in the Latest News section on the Monaco Growth Forums website. https://monacogrowthforums.com
Looking through the companies presented at the Spring 2016 MGF, the Pot Stock at that conference TRTC saw a huge and sustained bump in it's PPS right after the conference. Still researching this company to see how much it benefited from the MGF conference if at all, but from the chart, it looks like it did by a lot. http://finance.yahoo.com/quote/TRTC?p=TRTC
Also, there will be international media coverage of the conference.
I AGREE !!!!
All the language about "going concern" is boilerplate legal jargon that is included on all 10Ks of a company that is pre-revenue. That is nothing you need to worry about and basically the legal jargon way of saying "we can't guarantee anything".
New investors don't realize that when companies put out public statements they have to be very careful to disclose all possible negatives and never say stuff that can be construed as exaggerating. Otherwise some attorney will file a class action lawsuit if the stock goes down during the timeframe following the statement. It happens kind of a lot on the big boards. That's why when someone like Bob Iger, CEO of Disney, is doing an interview he is very careful of what he says and sometimes it sounds like he's downplaying the company's projections or even in one case he was outright negative when cord-cutting accelerated and cable companies began losing cable subscriptions and therefore Disney was losing some ESPN audience. I was holding DIS at the time and decided to keep it because I knew they would figure it out... and they did.
OWCPs 10K was solid with no surprises and confirmed many positive aspects of the company.
Now we officially have Alon Sinai in the OWC Ltd. CEO role along with his COO position. I have a good feeling about this change.
In 5 days OWCP officers will be at the Monaco Conference and they'll be talking to 475 institutional investors from over 44 countries, including heads of family offices, fund managers, and private asset managers from major institutions.
They invited Dr. Yehuda Baruch to be a Keynote Speaker. All eyes will be on OWCP.
For anyone wondering about the names on the patents.
The Applicant is :
One World Cannabis Ltd.
Beit Dvir 2nd Floor
22 Shacham Street
4951722 Petach Tikva / IL
These provisional patents are filed by and any protected IP resulting from them is wholly owned by OWC.
Anything that any of the company management, officers, Doctors, and employees do, is under the umbrella of OWC and that IP is owned by OWC/OWCP.
I'm a 100% sure that all said workers for OWC/OWCP have signed both non-disclosure agreements & non-compete agreements.
Actually OWC has an office in a 7 story modern office building and is about 2 miles from TEVA offices. An investor and poster on these boards has physically gone there and met with Ziv. That's all very real and I have seen the pictures that he sent me. Perhaps he will chime in if he reads this.
Please don't make false claims.
What Type of Investors Attend Monaco Growth Forums?
Cannabinoids In Marijuana May Be The Secret Cure For Itchy Skin
BY JANISSA DELZO ON 04/18/17 AT 4:29 PM
Cannabinoids may be an effective treatment for various skin diseases, according to research published in the Journal of the American Academy of Dermatology.
Researchers at the University of Colorado Anshutz Medical Campus analyzed current literature on the topic and found pharmaceuticals, like topical creams, containing cannabinoids may help fight eczema, psoriasis, atopic and contact dermatitis. The term “cannabinoids” refers to a number of chemical compounds found in the marijuana plant, such as THC and CBD.
“Perhaps the most promising role for cannabinoids is in the treatment of itch,” said the study’s senior author Dr. Robert Dellavalle, in a press release.
Dellavalle noted in one, small study, some of the participants who applied a cannabinoid cream for 3 weeks had their severe itching completely eliminated.
He believes the reason the treatments may be effective is due to their anti-inflammatory properties. Some studies have found THC, the main ingredient in marijuana, reduces inflammation in mice.
A majority of the studies Dellavalle and his colleagues reviewed used animals models, he notes. Large-scale clinical trials need to be conducted to better understand the effect of cannabinoids on human skin diseases. Although more research is needed, he believes that cannabinoids without psychotropic effects may be a good option for people who have not benefited from prior skin medications; however, he does not recommend this for those with cancer.
“These diseases cause a lot of problems for people and have a direct impact on their quality of life,” said Dellavalle. “The treatments are currently being bought over the internet and we need to educate dermatologists and patients about the potential uses of them.”
Skin diseases are common worldwide and affect more than 1 in 4 Americans, according to a previous study.
www.ibtimes.com/cannabinoids-marijuana-may-be-secret-cure-itchy-skin-2526983
Let's not forget the potential for OWCP doing a JV or being acquired by the likes of TEVA. The big league investors that will be attending the MGF conference in 5 days will be aware of the interest TEVA had in OWCP. OWCP turned it down, but I can see a large investor getting involved and taking OWCP further along so that it can then be acquired by big pharma for a much higher valuation.
Article about the TEVA interest in OWCP:
(JNi.media) Israeli Pharmaceutical company Teva appears to be moving into the medical marijuana market, and a pending acquisition could partially relieve the pain of its top drug, Copaxone, going off patent.
Teva, according to a report by The Marker, has made an offer for One World Cannabis (OWC) to purchase the rights to the company’s patents. One World is developing treatments using the compound in cannabis to treat chronic pain, multiple myeloma and other conditions.
OWC recently reported a study by the Sheba Medical Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment using the cannabis plant’s active ingredients. OWC is still in the early stages of developing a drug, but the company expects the resultant treatment to be licensed and available by prescription to those patients with myeloma entitled to cannabis-based treatments.
OWC has hired Dr. Yehuda Baruch, former head of Israel’s Ministry of Health’s Cannabis Unit as Director of Research.
Multiple myeloma is the second most common blood cancer after non-Hodgkin lymphoma. It affects six out of every 100,00 people and attacks the white blood cells, which produce antibodies that fight infection. The malignant cancer cells collect in the bone marrow where they disrupt the normal production of white blood cells. The disease is diagnosed by a blood test and is considered incurable but treatable with steroids, chemotherapy or proteasome inhibitors. The survival rate is 45% for five years.
The news of Teva’s proposal to buy OWC cannabis patents comes with the announcement by Cannabics Pharmaceuticals that it was appointing two Teva executives, Ika Abravanel and Dr. Sigalit Ariely-Portnoy, to its advisory board.
Cannabics is based in Maryland and, like OWC, is developing treatments through isolating the active ingredients in cannabis.
Abravanel has been named senior adviser in the field of operational and strategic planning. He served as Chief Integration Officer, and focused on Teva’s acquisitions and joint ventures. Abravanel was instrumental in providing strategies for the post-merger integration process of acquisitions and was on the steering committee of PGT, a joint venture between Procter & Gamble and Teva.
Dr. Sigalit Ariely-Portnoy was named as senior adviser in the field of regulation, validation and quality. She managed Teva’s largest plant worldwide, was President of Israel’s chapter of the Parenteral Drug Association and manages Gsap, a biotechnology consulting firm.
It may seem like a good idea for Teva to branch out with participation in the American medical cannabis industry and with acquiring patents from homegrown medical marijuana companies, since it will soon lose patent protection for its star drug, Copaxone, which has the leading treatment for multiple sclerosis.
Teva is currently trying to buy its competitors, such as Mylan, which has so far resisted Teva’s advances, even though the latter has raised the bid by $3 billion. Not only has Mylan rejected the offer, but chairman Robert Coury said a deal would be illegal. Teva may resort to a hostile bid if Mylan fails to secure an acquisition of Perrigo, which has resisted Mylan’s raised bid.
Like any suitor, Teva is trying to make itself more attractive, and with added feathers in its cap, it might appeal to Mylan shareholders.
One advantage is that in February, the FDA said it would consider Teva’s application for an extended-release, abuse-deterrent form of the active ingredient in the painkiller Vicodin. Vicodin is a highly popular drug, but it is also vulnerable to abuse, so Teva’s entry into the market may be a boon for Vicodin users, doctors and for Teva. In this light, Teva’s bid for OWC’s patents also makes sense for the company, and its move into the medical marijuana market is likely to be more than mere experimentation.
I agree and have the same gut feeling. This is churning like a volcano ready to explode again.
This Monaco Growth Forums event coming up in less than a week is a really big deal. Dr. Yehuda Baruch, OWCP’s CSO & CTO, will also be a Keynote Speaker at MGF’s Cocktail Reception on Wednesday, April 26th. The keynote topic will be “Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.” https://monacogrowthforums.com/2017/04/owc-pharmaceutical-research-corp-to-present-at-monaco-growth-forums-in-monaco/
MMJ is a very hot emerging market that big investors want to be in and OWCP has been chosen to present their position in this space to 475 institutional investors from over 44 countries, including heads of family offices, fund managers, and private asset managers from major institutions. All attendees at MGF events foster a shared interest in high-growth companies. There will for sure be many institutional investors interested in OWCP. With solid financial backing OWCP can take off and blow expectations away. https://monacogrowthforums.com/about/
Check out the exposure OWCP is getting listed in the Latest News section on the Monaco Growth Forums website. https://monacogrowthforums.com
Looking through the companies presented at the Spring 2016 MGF, the Pot Stock at that conference TRTC saw a huge and sustained bump in it's PPS right after the conference. Still researching this company to see how much it benefited from the MGF conference if at all, but from the chart, it looks like it did by a lot. http://finance.yahoo.com/quote/TRTC?p=TRTC
Also there will be a lot media coverage of the conference.
AWESOME !!
----------------------------------
Interesting info from Monaco 8k. It looks like OWC will have not 1, not 2, not 3, but FOUR separate opportunities to introduce themselves to this investment community. The Welcome Reception, Company Presentations, One-on-One Meetings & Dr. Baruch's keynote Wednesday night. Now that's an action packed event, no doubt they will be speaking to many enlightened investors!
Tuesday, 25th April 2017
6:30pm – 8:00pm Welcome Reception at the Maison du Caviar featuring Cascina Ballarin Premium Wines
Wednesday, 26th April 2017 - Monaco
9:30am – 10:15am Coffee and Pastries Served
10:30am – 12:55pm Company Presentations
1:00pm – 2:15pm Seated buffet lunch
2:30pm – 5:30pm One-on-One Meetings between delegates and company representative in 30-minute increments at the Wine Palace at the Yacht Club.
5:30pm – 7:00pm Italian Barolo Wine Tasting Reception at the Wine Palace at the Yacht Club featuring Cascina Ballarin Premium Wines
8:00pm – 10:30pm Three-Course Gourmet Gala Dinner at Maison du Caviar (By invitation only)
Quote:
The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring, Edition, on April 25th - 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical's approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP's CSO& CTO will also be a Keynote Speaker at MGF's Cocktail Reception on Wednesday, April 26th. The keynote topic will be "Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.
Sources:
https://monacogrowthforums.com/schedule/
http://www.otcmarkets.com/stock/OWCP/news?id=156037
_____________________________
How do you know? You can't predict the future.
Dude the Illuminati will keep the internet and markets going regardless of the anarchy in the streets. Also those with psoriasis will do anything to get the OWC cream.
Going to $18 in 2018!!!!!!
Keep in mind there are competitors in this space. They are adamantly protecting their IP until it is secure. They have said so in a recent 8K. I too would love full detail updates of everything they're doing, but if they tip off the competition and lose IP or IP opportunities then we lose out. They're doing the tests and clinical trials, their stating certain significant claims about their progress. People that suffer from psoriasis know how bad it sucks to have that skin condition. I have seen for myself the healing properties of cannabis oil and believe that OWCP has a real remedy in their pipeline for the awful skin condition known as psoriasis. When the psoriasis cream becomes available anywhere in the world, it will be a game changer and the stock price will likely go to double digits.
Today is tax day and lots of traders are using cash on hand to pay the IRS. Keep in mind a lot of traders made a lot of money in 2016 and they have to pay taxes. All the markets have been way down all day today.
The next huge catalyst is the Monaco Growth Forums next week with Dr. Yehuda Baruch as a Keynote Speaker.
This conference will likely result in some very deep pockets investing in OWCP.
How much it will affect the PPS, we shall soon see. Can it go up over $3? Yea it can.
Today is a buying opportunity, get the position you want while you can.
It's not uncommon for a biotech company (real companies) to go public with things in the pipeline and nothing yet on the market. They are protecting their IP until it is completely secured.
They are pursuing investors and will likely get a substantial placement for restricted shares after the Monaco Growth Forums (MGF) next week. The fact that the MGF chose Dr. Yehuda Barach as a Keynote speakers speaks a lot to the reputation he has as a leader in this field.
I was glad to see more transparency in how the Officers will be compensated. It also makes me feel more comfortable to know that they have disclosed this ESOP set up during 2016 which awards them share options that are held by a trustee and vest after a period of two years. Why is this important to me? Because now it is transparent and clear that the top management will receive a lot of shares as described below and this is a serious driver and motivator for this management team to make serious strides forward and the better they do the higher the stock price will go and directly affect their payoff. It also motivates them to get the company and stock to a point where they can uplist. These kind of incentive programs are often used in companies to motivate the management team to perform and meet progress deadlines and goals.
The most important part to me is this:
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Back to Table of Contents
The table below provides information regarding the beneficial ownership of the common stock as of March 31, 2017, of (1) each person or entity who owns beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) each of the Named Executive Officers, (4) our directors and officers as a group and (5) certain employees of our subsidiary OWC. Except as otherwise indicated, and subject to applicable community property laws, we believe the persons named in the table have sole voting and investment power with respect to all shares of common stock held by them. Unless otherwise indicated below, the address for each beneficial owner listed is c/o OWC Pharmaceutical Research Corp., at 30 Shacham Street, P.O. Box 8324, Petach Tikva, 4918103, Israel.
Name of Beneficial Owner Shares of Common Stock Beneficially Owned (1) Percent of Class (2)
Mordechai Bignitz, Chief Executive Officer (3) 0 0 %
Shmuel De-Saban, Chief Financial Officer (3) 195,416 *
Dr. Yehuda Baruch, Chief Science Officer (3) 0 0%
All directors and executive officers as a group (3 persons) 195,416 *
Alon Sinai, COO and Interim CEO of OWC (3) 1,011,250 0.70 %
Yehuda Baruch, Director of Research and Regulatory Affairs for OWC (3) 2,120,000 1.46 %
* Less than one percent.
(1) Represents shares of common stock held as of March 31, 2017 plus shares of common stock that may be acquired upon exercise of options, warrants and other rights exercisable within 60 days of March 31, 2017.
(2) Based on 144,719,287 shares of our common stock outstanding as of March 31, 2017.
(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.
- 72 -
The Monaco Growth Forums next week will be huge for OWCP. It says a lot that Dr. Yehuda Baruch, Chief Science Officer of OWCP is considered as the world renowned leader in the sector of Cannabis bio-pharma research and will be a speaker at this prestigious event. Many deep pockets will be hearing from the man himself and it is very likely that big investors will invest in OWCP. Good days ahead.
Speakers
https://monacogrowthforums.com/speakers/
OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco
Spring Edition to Take Place 25th-26th April 2017
PR Newswire
PETACH TIKVA, Israel, April 17, 2017
The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring, Edition, on April 25th - 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical's approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP's CSO& CTO will also be a Keynote Speaker at MGF's Cocktail Reception on Wednesday, April 26th. The keynote topic will be "Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.
Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.
Mr. Mordechai Bignitz, Chairman and CEO commented, "We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.
"Andreea Porcelli, CEO and Founder of Monaco Growth Forums commented, "We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area."
For more information or to RSVP for the MGF Spring Conference event and one-on-one investor meetings with OWC Pharmaceutical Research Corp., contact Sevinc Bermek, Events Coordinator: sbermek@monacogrowthforums.com or visit https://monacogrowthforums.com/ .
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President has more than 20 years experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations-all of whom are also exclusively invited to match MFG's highly selective criteria. http://www.monacogrowthforums.com
Another article about this event.
http://oracledispatch.com/2017/04/18/owc-pharmaceutical-research-corp-otcmktsowcp-pops-front-key-monaco-appearance/
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Pops in Front of Key Monaco Appearance
By Jermaine Farmer - April 18, 2017
SHARE Facebook Twitter
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a penny play in the cannabis patch that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. The principal catalyst, we believe, is likely the development that the company is going to be a presenter at the Monaco Growth Forum next week, and the company’s Chief Science Officer is slated to be a keynote speaker.
Given that the company now has real data to discuss where efficacy of its psoriasis cream is concerned, one might see this as a good venue for management to make some more important announcements either about data or upcoming clinical study plans. It’s plausible to see the recent action as a reflection of this idea, particularly as the company’s spot at the event was likely available in some form on Friday (such as the Forum’s schedule page), when the stock went berserk on the upside.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) casts itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
Find out when OWCP stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, OWCP has been “invited to present at the Monaco Growth Forums Spring Edition, on April 25th – 26th at The Montepole Hotel in Monte Carlo, Monaco.”
During the event, management will introduce OWC Pharmaceutical’s approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP’s CSO& CTO will also be a Keynote Speaker at MGF’s Cocktail Reception on Wednesday, April 26th.
According to the release, the keynote topic will be “Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.”
Mr. Mordechai Bignitz, Chairman and CEO commented, “We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC’s unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.
Traders will note 31% added to share values of the company over the past week of action, but that move comes in the context of a larger bearish trend. That said, OWCP has a track record that includes a number of dramatic bounces. In addition, the stock has seen an influx in interest of late, with the stock’s recent average trading volume running 85% over what the stock has registered over the longer term.
In the news again!! This emerging market is gaining a lot of attention.
http://www.prnewswire.com/news-releases/legal...08253.html
AWESOME SUMMARY THANKS!!!
EXCELLENT SUMMARY!!
It's totally normal for a start up company to issue some stock as needed to operate. This management team has been very prudent in this regard, so even though there will be a little dilution the stock price will sore in my opinion as a result of all the catalyst that are coming this year.
OTC trades after/before hours do happen. I guess the MMs have that privilege. There was a trade of 300@1.17 at 4:05 pm and then another trade of 600@1.16 at 4:16 pm. Maybe they know something is coming.?!
Another trade just occurred of 600 shares @ $1.16 at 16:16.
Yes, I'm on schwab and the last trade was 300 shares @ 1.17 at 16:05
10 K coming today and will most likely be solid. Tomorrow is looking good.
This stock is a beast and can't be kept down no matter how much the shorts try. When they have to cover we're looking at $2+
$$OWCP$$
thanks for the insight
List of speakers at the Monaco Growth Forums in Monaco - April 25-26, 2017. (LINK)
This is the big leagues and there will be many investors with very deep pockets in attendance.
OWCP is speaking at this conference to cover the MMJ emerging markets because OWC is at the forefront of this space. We are still at ground floor entry here but it won't last long. Get in while you can, the close today will likely be well above 1$ and this stock will probably steadily climb all week. Too many catalyst happening now. Chance of a lifetime to retire early.
https://monacogrowthforums.com/speakers/
20,000 shares traded at 1$ in the last minute. Got whacked down to .98, then moved right back up to .99. They can't keep it down.
It's easy to see this up pressure. This is a perfect set up for a strong powerhour bust out. Last 20 minutes we'll get a new HOD and close high.
Come on dude... do a little bit of research. If the 15th falls on a weekend then the 10K is due on the following business day.
Train is leaving the station. Get on board while you can. This morning's announcement is huge. The 10K will be released sometime today and this stock is going up big and solid never to look back.
OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco
Spring Edition to Take Place 25th-26th April 2017
PR Newswire
PETACH TIKVA, Israel, April 17, 2017
PETACH TIKVA, Israel, April 17, 2017 /PRNewswire/ --
The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring, Edition, on April 25th - 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical's approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP's CSO& CTO will also be a Keynote Speaker at MGF's Cocktail Reception on Wednesday, April 26th. The keynote topic will be "Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.
Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.
Mr. Mordechai Bignitz, Chairman and CEO commented, "We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.
"Andreea Porcelli, CEO and Founder of Monaco Growth Forums commented, "We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area."
For more information or to RSVP for the MGF Spring Conference event and one-on-one investor meetings with OWC Pharmaceutical Research Corp., contact Sevinc Bermek, Events Coordinator: sbermek@monacogrowthforums.com or visit https://monacogrowthforums.com/ .
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President has more than 20 years experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations-all of whom are also exclusively invited to match MFG's highly selective criteria. http://www.monacogrowthforums.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Mordechai Bignitz Chairman and CEO
Email: mordechai.bignitz@owcpharma.com
Tel: +972-(0)3-770-8526
SOURCE OWC Pharmaceutical Research Corp.
OWCP.
OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Commenting on his investment, Mr. Michael Brath a Director of Michepro Holding Ltdsaid, "OWC is the perfect match to our investment strategy; they are pioneers in the field of medical cannabis clinical research and we see incredible value in the work they are doing which is exactly what has been missing from thisMMJ market. We decided to invest and partner with them because I believe that our resources across the EU will significantly accelerate their ability to commercialize those efforts throughout that market - initially with the psoriasis treatment, and then with other therapies as they come online"
http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-signs-investment-and-joint-venture-with-michepro-holdings-ltd-599813021.html
If you find more information on the Michepro agreement will you post it here even if it is positive or at least leaves one to believe that it may very well be legit?
Or is this forum all about discrediting companies only?
If you haven't seen this it's worth a read.
$OWCP - long and strong $$$$
We've all seen what this stock can do, and just last Wednesday it was a solid steady climb up 78%. It did pull back which means it's time to get shares still for around 1$ while you can before it's too late.
We all know what great potential OWCP has or we would be on this board. Waiting on the sideline is risking getting left behind. It's going to go up... when and how much no one can know for sure, but it will go up.
$OWCP - long and strong $$$$
OWCP. Took me 1 min on Google to find this on Medmar. Medmar LLC was on the list of companies who applied in Maryland for a preliminary licenses to process marijuana.
Here are the winners and losers in the race to grow medical marijuana in Maryland
Maryland regulators announced which 15 companies can grow medical marijuana in Maryland. The commission also announced 15 companies received preliminary licenses to process marijuana. Records obtained by the The Washington Post showed the people behind the companies that won and lost in bids for licenses. Read related: Select companies will be first in Md. to legally grow, process marijuana for medicine.
They weren't one of the 15 companies selected out of 144 companies that applied, but more companies will be getting licenses in the future.
MedMar is on this list and they have political ties with Robert DiPietro, the former mayor of Laurel, Md, who is involved.
Medmar LLC
ALSO APPLIED TO SELL AND PROCESS
Yehuda Baruch and Alon Sinai are executives at One World Cannabis, a publicly traded Israeli company that runs clinical trials studying the effect of cannabis on ailments as varied as migraines and PTSD. Robert DiPietro is the former mayor of Laurel, Md., who later registered as a lobbyist.
Steve Weinstein, chief executive
Who's involved
Steven Weinstein
Robert DiPietro
Ernest Roll
Alon Sinai
Yehuda Baruch
https://www.washingtonpost.com/graphics/local/md-marijuana/
Can you guys admit that there is documentation about Medmar now???
It bodes fine, they'll post it in the morning or after the market closes. All good.
Tomorrow should close in the 1.50-1.70 range, but it might surprise us all and break $2.
$OWCP - long and strong $$$$
Good Post, good DD.
$OWCP is ready to go up hard this week. Don't get left behind.
IMHO $OWCP is the best of the best in MMJ stocks and regardless of volatility in the pps, $OWCP will make many long investors rich. Good Luck.